
Mitochondrial Stack
MOTS-C + SS-31 + NAD+ — cellular bioenergetics research stack.
What it is
The Mitochondrial Stack combines MOTS-C (a 16-amino-acid mitochondrial-derived peptide), SS-31 (a cardiolipin-binding tetrapeptide) and NAD+ precursor loading to model cristae stabilization, oxidative-phosphorylation efficiency and redox homeostasis in bioenergetics research.
Mechanism of Action
MOTS-C activates AMPK and modulates nuclear gene programs controlling metabolic homeostasis; SS-31 selectively binds cardiolipin on the inner mitochondrial membrane to protect cristae architecture and electron-transport-chain coupling; NAD+ replenishes sirtuin- and PARP-dependent redox and repair pathways. Together they target biogenesis, membrane integrity and cofactor availability.
- Step 01Receptor Binding
Peptide engages target receptor with high affinity.
- Step 02Signal Cascade
Downstream intracellular pathways activate.
- Step 03Cellular Response
Gene expression and protein synthesis shift.
- Step 04Observed Outcome
Measurable change in the studied biomarker.
Potential research applications
Storage Guidelines
Store lyophilized at -20°C, protected from light. Reconstitute with bacteriostatic water; refrigerate at 2–8°C and use within 30 days.
Research Disclaimer
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Mitochondrial Stack is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
Citations & References
- 01Lee C, Zeng J, Drew BG, et al. · 2015The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metabolism. 21(3):443–454.
- 02Szeto HH. · 2014First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsBritish Journal of Pharmacology. 171(8):2029–2050.
- 03Rajman L, Chwalek K, Sinclair DA. · 2018Therapeutic potential of NAD-boosting molecules: the in vivo evidenceCell Metabolism. 27(3):529–547.
